Sanofi Pasteur Announces Favorable Phase II Study Results for Investigational Clostridium difficile Vaccine at the American Society for Microbiology Meeting

Results indicate vaccine generates an immune response against key toxins in volunteers and establish dosing for Phase III May 19, 2014 Sanofi Pasteur, the vaccines division of Sanofi , presented Phase II trial (H-030-012) results for an investigational vaccine for the prevention of Clostridium difficile (C. diff) infection (CDI) at the 114th General Meeting of the American Society for Microbiology …